The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: a dose-escalation phase I study
In fact, more than 30% of North American patients with RA also carry obesity, and this group tends to cycle through more medications before finding relief
We have partnered with a preferred pharmacy for discounted self pay rates.
Patients can choose between Wegovy, Zepbound, or compounded GLP-1 lozenges, drops, or injections and have the option to add premium coaching for personalized guidance
In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)